Market Analysis and Insights: Global Digital Inhalers Market
Due to the COVID-19 pandemic, the global Digital Inhalers market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Metered Dose Inhaler (MDI) accounting for % of the Digital Inhalers global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Digital Inhalers market size is valued at US$ million in 2021, while the US and Europe Digital Inhalers are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Digital Inhalers landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Digital Inhalers include Novartis, Propeller Health (ResMed), AstraZeneca Plc, Philips Respironics, Opko Health, Teva Pharmaceuticals, Adherium, Glenmark Pharmaceuticals and Pneuma Respiratory. etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Digital Inhalers Scope and Segment
Digital Inhalers market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Digital Inhalers market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Metered Dose Inhaler (MDI)
Dry Powder Inhaler (DPI)
Segment by Application
Hospital
Clinic
Others
By Company
Novartis
Propeller Health (ResMed)
AstraZeneca Plc
Philips Respironics
Opko Health
Teva Pharmaceuticals
Adherium
Glenmark Pharmaceuticals
Pneuma Respiratory
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE